Tokyo/Preliminary assays

From 2007.igem.org

(Difference between revisions)
(Procedure:)
(Result:)
Line 38: Line 38:
===Procedure: ===
===Procedure: ===
===Result: ===
===Result: ===
-
[[Tokyo/AHL assay Standard protocol |AHL assay Standard protocol ]]
 
===Conclusion: ===
===Conclusion: ===

Revision as of 14:01, 20 October 2007

Contents

AHL preparation

AHL assay

Date:

2007/09/06, 07

Purpose1:

To practive AHL assay.

Purpose2:

To check if AHL works.

Samples:


luxR + GFP in DH5a (AHL-activated promoter)
placQI + GFP in DH5a (pos. con.)
pSBΔP+ GFP (neg. con.)


ΔP = promoter deleted

Procedure:


The final concentration of AHL is 6 pM.

Result:

Conclusion:

6pM of AHL is not enough to activate the AHL-activated luxR promoter.

AHL assay

Date:

2007/09/15

Purpose:

check if lux-lac hybrid promoter works

Samples:


Lux-lac hybrid promoter (before blue light check)
Lux-lac hybrid promoter (after blue light check)
placQI (pos. con.)
modified A4 (promoter deleted) (neg. con.)

Procedure:

Result:

Conclusion:

OD correction

Date:

2007/09/21

Purpose:

Samples:

Procedure:

Result:

Conclusion:

Wash

Date:

20070925

Purpose:

Samples:

Procedure:

Result:

Conclusion:

Detailed AHL assay

Date:

20070925

Purpose:

Samples:

Procedure:

Result:

Conclusion:

New-AHL assay

Date:

20070926

Purpose:

Samples:

Procedure:

Result:

Conclusion:

Lux-lac hybrid promoter Check

Luxlachybrid.jpg

Date:

2007/09/20, 21

Purpose 1:

To check if LacI hybrid promoter is activated by AHL and repressed by LacI.

Purpose 2:

To obtain parameters of LacI hybrid promoter for computational simulation.

Samples:


1. pTrc99A + [LacI hybrid promoter – GFP] (LacI+)
2. pBR322 TetR + [LacI hybrid promoter – GFP] (lacI-)
3. pTrc99A + [placQI – GFP] (placQI is constitutive promoter)
4. pTrc322 TetR + [LacI promoter – GFP]
5. pBR322 TetR + [LacI promoter – GFP]


Repressor LacI expression:
pTrc99A expresses LacI
pBR322 TetR does NOT express LacI


Antibiotics resistance:
pTrc99A gives ampicillin-resistance
pBR322 TetR gives ampicillin-resistance
[LacI hybrid promoter – GFP] gives kanamicin-resistance
[placQI – GFP] gives kanamicin-resistance

Procedure: